SCHEMBL16624283

SCHEMBL16624283

COC(=O)CC(=O)C(C)OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.46
GAA P10253 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
TSHR P16473 4/20 0.43
HSD17B10 Q99714 3/20 0.40
MAPT P10636 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
CA12 O43570 2/20 0.33
CA14 Q9ULX7 2/20 0.33
KMT2A Q03164 2/20 0.33
TET2 Q6N021 1/20 0.33
MEN1 O00255 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
LMNA P02545 2/20 0.32
KDM4E B2RXH2 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546479 0.82 GAA (0.56) MGAMGAASIMGAM2TSHR
SCHEMBL971753 0.82 GAA (0.56) MGAMGAASIMGAM2TSHR
SCHEMBL17292940 0.81 CYP2D6 (0.40) GAATSHRCA12CA14KMT2A
SCHEMBL18787771 0.81 CYP2D6 (0.40) GAATSHRCA12CA14KMT2A
SCHEMBL17292943 0.81 CYP2D6 (0.40) GAATSHRCA12CA14KMT2A
SCHEMBL262554 0.80 LDHA (0.38) TSHRMAPTCYP2C19LMNAALDH1A1
SCHEMBL21294536 0.80 LDHA (0.38) TSHRMAPTCYP2C19LMNAALDH1A1
SCHEMBL4454619 0.80 MGAM (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL3233649 0.80 TSHR (0.32) TSHRCA12CA9ALDH1A1SMN1; SMN2
SCHEMBL14399730 0.79 MGAM (0.46) MGAMGAASIMGAM2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099777-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR4, SSTR2 MGAM 1562/4885GAA 1742/4885SI 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.